The delisting risk is removed, but Nasdaq Panel Monitor oversight and the halted stock mean no near-term trading liquidity. Monitor for any Nasdaq lift of the trading halt and for the outcome of the Antigua SSM board proceedings, which could unlock a path to resumption. The deep operating losses and internal control weaknesses argue against any positive re-rating until fundamental recovery is demonstrated.
Price Chart
Executive Summary
Sinovac regained Nasdaq listing compliance following the long-delayed filing of its FY2025 20-F on June 5, 2026, which confirmed severe operational deterioration with a -$59.7M net loss vs. +$90.9M profit in 2024. The delisting threat is removed, but Nasdaq continues a Mandatory Panel Monitor through May 2027, and the stock remains halted (since Feb 2019) with deeply impaired fundamentals and material internal control weaknesses.
Key Facts
- Sinovac received a Nasdaq notification (June 10, 2026) confirming regained compliance with Listing Rule 5250(c)(1) after filing its FY2025 20-F on June 5, 2026
- The company remains under a Mandatory Panel Monitor per Listing Rule 5815(d)(4)(B) until May 20, 2027
- The previously scheduled hearing before the Hearings Panel has been canceled
- FY2025 annual report (20-F) disclosed a -$59.7M net loss attributable to shareholders vs. +$90.9M in 2024, driven by $137.2M PP&E impairments, $65.6M goodwill/IPR&D write-offs, and a $109.8M currency loss
- Revenue was $386.0M (+6.8% YoY), gross margin 67.9%, but operating loss was -$490.1M
- A $3.96B dividend upstreamed from subsidiaries nearly drained retained earnings from $6.84B to $2.82B; material weaknesses in internal controls persist
- Trading has been halted since February 2019 and remains halted as of this filing
Financial Impact
Compliance regained eliminates immediate delisting risk but does not change halted trading status or the deeply negative FY2025 financials: -$59.7M net loss, -$490.1M operating loss, $137.2M impairments, $65.6M write-offs. Retained earnings drained by $3.96B dividend upstreaming.
Risk Factors
- Stock remains halted since Feb 2019 with no stated timeline for trading resumption
- Mandatory Panel Monitor through May 2027 imposes ongoing compliance oversight
- Persistent material weaknesses in internal controls increase restatement risk
- Drained retained earnings ($6.84B to $2.82B) limit financial flexibility
- Heavy operating losses (-$490.1M) on only $386M revenue raise going-concern questions notwithstanding compliance status
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-068483 |
| Document: ea029474501ex99-1.htm | 0001213900-26-068483 |
| Document: 0001213900-26-068483-index-headers.html | 0001213900-26-068483 |
| Document: 0001213900-26-068483-index.html | 0001213900-26-068483 |
| Document: 0001213900-26-068483.txt | 0001213900-26-068483 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 10w ago | 6-K | — | awaiting T+5 | — | — |
Jul 15, 2026 14w ago | 6-K | — | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | 6-K | $6.47 $6.47 | · 0.00% | ▼ −2.62% | — |
Jun 5, 2026 20w ago | 20-F | $6.47 $6.47 | · 0.00% | ▲ +0.57% | — |
May 29, 2026 21w ago | 6-K | $6.47 $6.47 | · 0.00% | ▼ −2.75% | — |
May 21, 2026 22w ago | 6-K | $6.47 $6.47 | · 0.00% | ▼ −1.85% | — |
May 8, 2026 24w ago | 6-K | $6.47 $6.47 | · 0.00% | ▼ −0.09% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers